223 related articles for article (PubMed ID: 12477829)
1. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic.
McGettigan JP; Pomerantz RJ; Siler CA; McKenna PM; Foley HD; Dietzschold B; Schnell MJ
J Virol; 2003 Jan; 77(1):237-44. PubMed ID: 12477829
[TBL] [Abstract][Full Text] [Related]
2. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.
McGettigan JP; Naper K; Orenstein J; Koser M; McKenna PM; Schnell MJ
J Virol; 2003 Oct; 77(20):10889-99. PubMed ID: 14512539
[TBL] [Abstract][Full Text] [Related]
3. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.
McGettigan JP; Sarma S; Orenstein JM; Pomerantz RJ; Schnell MJ
J Virol; 2001 Sep; 75(18):8724-32. PubMed ID: 11507217
[TBL] [Abstract][Full Text] [Related]
4. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
McGettigan JP; Koser ML; McKenna PM; Smith ME; Marvin JM; Eisenlohr LC; Dietzschold B; Schnell MJ
Virology; 2006 Jan; 344(2):363-77. PubMed ID: 16226782
[TBL] [Abstract][Full Text] [Related]
5. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines.
Siler CA; McGettigan JP; Dietzschold B; Herrine SK; Dubuisson J; Pomerantz RJ; Schnell MJ
Virology; 2002 Jan; 292(1):24-34. PubMed ID: 11878905
[TBL] [Abstract][Full Text] [Related]
6. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene.
Cenna J; Tan GS; Papaneri AB; Dietzschold B; Schnell MJ; McGettigan JP
Vaccine; 2008 Nov; 26(50):6405-14. PubMed ID: 18804506
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a single-cycle rabies virus-based vaccine vector.
Gomme EA; Faul EJ; Flomenberg P; McGettigan JP; Schnell MJ
J Virol; 2010 Mar; 84(6):2820-31. PubMed ID: 20053743
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
9. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
Viner KM; Girgis N; Kwak H; Isaacs SN
Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733
[TBL] [Abstract][Full Text] [Related]
10. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque.
McKenna PM; Aye PP; Dietzschold B; Montefiori DC; Martin LN; Marx PA; Pomerantz RJ; Lackner A; Schnell MJ
J Virol; 2004 Dec; 78(24):13455-9. PubMed ID: 15564456
[TBL] [Abstract][Full Text] [Related]
12. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.
Marsac D; Loirat D; Petit C; Schwartz O; Michel ML
J Virol; 2002 Aug; 76(15):7544-53. PubMed ID: 12097567
[TBL] [Abstract][Full Text] [Related]
13. Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein.
Mebatsion T
J Virol; 2001 Dec; 75(23):11496-502. PubMed ID: 11689631
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector.
Giel-Moloney M; Rumyantsev AA; David F; Figueiredo M; Feilmeier B; Mebatsion T; Parrington M; Kleanthous H; Pugachev KV
Vaccine; 2017 Dec; 35(49 Pt B):6898-6904. PubMed ID: 28899628
[TBL] [Abstract][Full Text] [Related]
15. A recombinant canine distemper virus expressing a modified rabies virus glycoprotein induces immune responses in mice.
Li Z; Wang J; Yuan D; Wang S; Sun J; Yi B; Hou Q; Mao Y; Liu W
Virus Genes; 2015 Jun; 50(3):434-41. PubMed ID: 25764477
[TBL] [Abstract][Full Text] [Related]
16. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
17. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
18. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity.
Faul EJ; Wanjalla CN; McGettigan JP; Schnell MJ
Virology; 2008 Dec; 382(2):226-38. PubMed ID: 18945463
[TBL] [Abstract][Full Text] [Related]
19. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity.
Faber M; Faber ML; Papaneri A; Bette M; Weihe E; Dietzschold B; Schnell MJ
J Virol; 2005 Nov; 79(22):14141-8. PubMed ID: 16254349
[TBL] [Abstract][Full Text] [Related]
20. Biological and immunogenic properties of rabies virus glycoprotein expressed by canine herpesvirus vector.
Xuan X; Tuchiya K; Sato I; Nishikawa Y; Onoderaz Y; Takashima Y; Yamamoto A; Katsumata A; Iwata A; Ueda S; Mikami T; Otsuka H
Vaccine; 1998; 16(9-10):969-76. PubMed ID: 9682345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
